Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T21617
(Former ID: TTDI01551)
|
|||||
| Target Name |
Signal transduction unspecific (ST)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Lupus erythematosus [ICD-11: 4A40] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | Forigerimod | Drug Info | Phase 3 | Systemic lupus erythematosus | [2] | |
| 2 | OMN-54 | Drug Info | Phase 1 | Solid tumour/cancer | [3] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Forigerimod | Drug Info | [4], [5] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | OMN-54 | Drug Info | [1] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar;8(2):311-22. | |||||
| REF 2 | ClinicalTrials.gov (NCT01240694) A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT01555242) A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas. U.S. National Institutes of Health. | |||||
| REF 4 | Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873-83. | |||||
| REF 5 | Clinical pipeline report, company report or official report of ImmuPharma. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.